Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) EBITDA (2022 - 2026)

Envoy Medical's EBITDA history spans 5 years, with the latest figure at -$4.4 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 12.82% to -$4.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$23.1 million, a 18.4% decrease, with the full-year FY2025 number at -$23.8 million, down 14.2% from a year prior.
  • EBITDA hit -$4.4 million in Q1 2026 for Envoy Medical, up from -$6.6 million in the prior quarter.
  • Over the last five years, EBITDA for COCH hit a ceiling of $1.6 million in Q3 2023 and a floor of -$13.3 million in Q1 2023.
  • Historically, EBITDA has averaged -$5.5 million across 5 years, with a median of -$5.0 million in 2025.
  • The widest YoY moves for EBITDA: up 216.39% in 2023, down 1369.67% in 2023.
  • Tracing COCH's EBITDA over 5 years: stood at -$11.5 million in 2022, then soared by 57.35% to -$4.9 million in 2023, then grew by 5.66% to -$4.6 million in 2024, then tumbled by 42.55% to -$6.6 million in 2025, then surged by 33.92% to -$4.4 million in 2026.
  • Business Quant data shows EBITDA for COCH at -$4.4 million in Q1 2026, -$6.6 million in Q4 2025, and -$6.5 million in Q3 2025.